Group 1 - The core point of the article is that Zhongyi Technology (SZ 301208) held its eighth meeting of the fifth board of directors on October 23, 2025, to review the third quarter report for 2025 [1] - For the first half of 2025, Zhongyi Technology's revenue composition is as follows: banks account for 48.11%, other financial institutions for 26.57%, other industries for 17.76%, manufacturing for 3.94%, and government for 3.61% [1] - As of the report, Zhongyi Technology has a market capitalization of 4.8 billion yuan [1] Group 2 - The article mentions that Chinese innovative drugs have sold overseas licenses worth 80 billion USD this year [1] - There is a discussion about the hot secondary market in biomedicine, while the primary market is facing challenges in fundraising [1]

Group 1 - The core point of the article is that Yaoyigou (SZ 300937) held its third meeting of the fourth board of directors on October 23, 2025, via telecommunication voting, discussing the proposal to amend certain company systems [1] - For the first half of 2025, Yaoyigou's revenue composition was as follows: pharmaceutical distribution (contract distribution + market comparison) accounted for 47.09%, pharmaceutical sales (direct procurement) accounted for 41.92%, pharmaceutical manufacturing and OEM business accounted for 8.55%, and other businesses accounted for 2.44% [1] - As of the time of reporting, Yaoyigou's market capitalization was 2.7 billion yuan [1] Group 2 - The article mentions that Chinese innovative drugs have sold overseas licenses worth 80 billion USD this year, highlighting the hot secondary market in biomedicine while questioning the cold fundraising environment in the primary market [1]